These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 20845738)
1. [Immunity against influenza virus infection]. Takada A Nihon Rinsho; 2010 Sep; 68(9):1625-30. PubMed ID: 20845738 [TBL] [Abstract][Full Text] [Related]
2. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118 [TBL] [Abstract][Full Text] [Related]
4. Trends in development of the influenza vaccine with broader cross-protection. Stropkovská A; Janulíková J; Varecková E Acta Virol; 2010; 54(1):7-19. PubMed ID: 20201609 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Tamura S; Tanimoto T; Kurata T Jpn J Infect Dis; 2005 Aug; 58(4):195-207. PubMed ID: 16116250 [TBL] [Abstract][Full Text] [Related]
6. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity. Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633 [TBL] [Abstract][Full Text] [Related]
7. Age-related changes in magnitude and diversity of cross-reactive CD4+ T-cell responses to the novel pandemic H1N1 influenza hemagglutinin. Subbramanian RA; Basha S; Brady RC; Hazenfeld S; Shata MT; Bernstein DI Hum Immunol; 2010 Oct; 71(10):957-63. PubMed ID: 20650295 [TBL] [Abstract][Full Text] [Related]
8. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant. Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854 [TBL] [Abstract][Full Text] [Related]
9. Pandemic preparedness: toward a universal influenza vaccine. Roose K; Fiers W; Saelens X Drug News Perspect; 2009 Mar; 22(2):80-92. PubMed ID: 19330167 [TBL] [Abstract][Full Text] [Related]
10. Keeping the memory of influenza viruses. Combadière B; Sibéril S; Duffy D Pathol Biol (Paris); 2010 Apr; 58(2):e79-86. PubMed ID: 20303671 [TBL] [Abstract][Full Text] [Related]
11. Heterosubtypic antibodies to influenza A virus have limited activity against cell-bound virus but are not impaired by strain-specific serum antibodies. Wyrzucki A; Bianchi M; Kohler I; Steck M; Hangartner L J Virol; 2015 Mar; 89(6):3136-44. PubMed ID: 25552718 [TBL] [Abstract][Full Text] [Related]
12. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia. Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232 [TBL] [Abstract][Full Text] [Related]
13. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses. Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216 [TBL] [Abstract][Full Text] [Related]
14. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses. Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208 [TBL] [Abstract][Full Text] [Related]
15. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Tamura S; Kurata T Jpn J Infect Dis; 2004 Dec; 57(6):236-47. PubMed ID: 15623947 [TBL] [Abstract][Full Text] [Related]
16. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470 [TBL] [Abstract][Full Text] [Related]
18. Recognition of influenza virus hemagglutinin by subtype-specific and cross-reactive proliferative T cells: contribution of HA1 and HA2 polypeptide chains. Katz JM; Laver WG; White DO; Anders EM J Immunol; 1985 Jan; 134(1):616-22. PubMed ID: 3871116 [TBL] [Abstract][Full Text] [Related]
19. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. Bianchi E; Liang X; Ingallinella P; Finotto M; Chastain MA; Fan J; Fu TM; Song HC; Horton MS; Freed DC; Manger W; Wen E; Shi L; Ionescu R; Price C; Wenger M; Emini EA; Cortese R; Ciliberto G; Shiver JW; Pessi A J Virol; 2005 Jun; 79(12):7380-8. PubMed ID: 15919893 [TBL] [Abstract][Full Text] [Related]
20. Seed viruses containing novel avian HA and NA antigens for prevention against potential influenza pandemic. Li S; Perdue ML; Patzer E Dev Biol (Basel); 2002; 110():135-41. PubMed ID: 12477316 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]